GASTROCROM (cromolyn sodium)
SYSTEMIC MASTOCYTOSIS
AZUR PHARMA, IN
Indication
Systemic mastocytosis
Systemic mastocytosis is a rare clonal hematologic neoplasm characterized by the abnormal proliferation and accumulation of genetically altered mast cells within extracutaneous tissues, most commonly the bone marrow, liver, spleen, gastrointestinal tract, and lymph nodes. Read more about Systemic mastocytosis
10 drugs 9 manufacturers
Drugs that treat it
Common Systemic mastocytosis therapies.
CROMOLYN SODIUM
SYSTEMIC MASTOCYTOSIS
PACK PHARMACEUT
CROMOLYN SODIUM
SYSTEMIC MASTOCYTOSIS
PACK PHARMACEUT
CROMOLYN SODIUM
SYSTEMIC MASTOCYTOSIS
WALLACE PHARMAC
CROMOLYN SODIUM
MAST-CELL STABILIZER-TYPE ANTI-ALLERGY SYSTEMIC AGENTS·SYSTEMIC MASTOCYTOSIS
RISING PHARM
CROMOLYN SODIUM
PULMONARY MAST-CELL STABILIZER-TYPE ANTI-INFLAMMATORY AGENTS·SYSTEMIC MASTOCYTOSIS
MICRO LABS USA,
GASTROCROM (cromolyn sodium)
MAST-CELL STABILIZER-TYPE ANTI-ALLERGY SYSTEMIC AGENTS·SYSTEMIC MASTOCYTOSIS
Viatris Specialty
CROMOLYN SODIUM
MAST-CELL STABILIZER-TYPE ANTI-ALLERGY SYSTEMIC AGENTS·SYSTEMIC MASTOCYTOSIS
OMNIVIUM PHARMA
GASTROCROM (cromolyn sodium)
MAST-CELL STABILIZER-TYPE ANTI-ALLERGY SYSTEMIC AGENTS·SYSTEMIC MASTOCYTOSIS
Viatris Specialty
Filter & compare in the drug finder →Opens the drug finder with Systemic mastocytosis preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonSystemic mastocytosis is a rare clonal hematologic neoplasm characterized by the abnormal proliferation and accumulation of genetically altered mast cells within extracutaneous tissues, most commonly the bone marrow, liver, spleen, gastrointestinal tract, and lymph nodes.
It predominantly affects adults and is driven in most patients by activating somatic mutations in the *KIT* receptor tyrosine kinase gene, such as KIT D816V.
Clinical manifestations range from indolent to aggressive disease, driven both by mast cell mediator release—causing episodic flushing, pruritus, abdominal pain, hypotension, and anaphylaxis—and by tissue infiltration that can lead to cytopenias, organomegaly, and end-organ dysfunction.
- cancer.gov
Systemic mastocytosis is a rare clonal hematologic neoplasm characterized by the abnormal proliferation and accumulation of genetically altered mast cells within extracutaneous tissues, most commonly the bone marrow, liver, spleen, gastrointestinal tract, and lymph nodes Clinical manifestations range from indolent to aggressive disease, driven both by mast cell mediator release—causing episodic flushing, pruritus, abdominal pain, hypotension, and anaphylaxis—and by tissue infiltration that can l...
- medlineplus.gov
Systemic mastocytosis is a rare clonal hematologic neoplasm characterized by the abnormal proliferation and accumulation of genetically altered mast cells within extracutaneous tissues, most commonly the bone marrow, liver, spleen, gastrointestinal tract, and lymph nodes It predominantly affects adults and is driven in most patients by activating somatic mutations in the *KIT* receptor tyrosine kinase gene, such as KIT D816V
- nih.gov
Systemic mastocytosis is a rare clonal hematologic neoplasm characterized by the abnormal proliferation and accumulation of genetically altered mast cells within extracutaneous tissues, most commonly the bone marrow, liver, spleen, gastrointestinal tract, and lymph nodes
- mayoclinic.org
It predominantly affects adults and is driven in most patients by activating somatic mutations in the *KIT* receptor tyrosine kinase gene, such as KIT D816V Clinical manifestations range from indolent to aggressive disease, driven both by mast cell mediator release—causing episodic flushing, pruritus, abdominal pain, hypotension, and anaphylaxis—and by tissue infiltration that can lead to cytopenias, organomegaly, and end-organ dysfunction
- medlineplus.gov
Clinical manifestations range from indolent to aggressive disease, driven both by mast cell mediator release—causing episodic flushing, pruritus, abdominal pain, hypotension, and anaphylaxis—and by tissue infiltration that can lead to cytopenias, organomegaly, and end-organ dysfunction
- bioontology.org
Clinical manifestations range from indolent to aggressive disease, driven both by mast cell mediator release—causing episodic flushing, pruritus, abdominal pain, hypotension, and anaphylaxis—and by tissue infiltration that can lead to cytopenias, organomegaly, and end-organ dysfunction
Personalize your experience
Follow Systemic mastocytosis and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.